Mycobacterium abscessus: Challenges in diagnosis and treatment

Current Opinion in Infectious Diseases

Volumn 27, Issue 6, 2014, Pages 506-510

  Benwill, Jeana L ^a   Wallace, Richard J ^a,b  

^a Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Mycobacterium abscessus; Mycobacterium bolletii; Mycobacterium massiliense; Nontuberculous mycobacteria

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CLARITHROMYCIN; ERYTHROMYCIN; IMIPENEM; LINEZOLID; MACROLIDE; METHYLTRANSFERASE; MOXIFLOXACIN; TIGECYCLINE; ANTIINFECTIVE AGENT; DNA BINDING PROTEIN; ETV5 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CYSTIC FIBROSIS; DISEASE COURSE; DYSPHONIA; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; LUNG INFECTION; LUNG TRANSPLANTATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM ABSCESSUS INFECTION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; REVIEW; RSPL GENE; TREATMENT OUTCOME; WATER SUPPLY; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; COMPLICATION; DNA SEQUENCE; DOSE RESPONSE; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PATHOPHYSIOLOGY; RESPIRATORY TRACT INFECTIONS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; AZITHROMYCIN; CYSTIC FIBROSIS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPIRATORY TRACT INFECTIONS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84927800163     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000104     Document Type: Review

References (25)

1. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
2. Thomson R, Tolson C, Sidjabat H, et al. Mycobacterium abscessus isolated from municipal water- A potential source of human infection. BMC Infect Dis 2013; 13:241.
3. Thomson R, Tolson C, Carter R, et al. Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM. J Clin Microbiol 2013; 51:3006-3011.
4. Mullis SN, Falkinham JO III. Adherence and biofilm formation of Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium abscessus to household plumbing materials. J Appl Microbiol 2013; 115: 908-914.
5. Tettelin H, Davidson RM, Agrawal S, et al. High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaks. Emerg Infect Dis 2014; 20:364-371.
6. Teng SH, Chen CM, Lee MR, et al. Matrix-assisted laser desorption ionizationtime of flight mass spectrometry can accurately differentiate between Mycobacterium masilliense (M. Abscessus subspecies bolletti) and M. Abscessus (sensu stricto). J Clin Microbiol 2013; 51:3113-3116.
7. Sassi M, Drancourt M. Genome analysis reveals three genomospecies in Mycobacterium abscessus. BMC Genomics 2014; 15:359.
8. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard-second edition. CLSI document 2011; M24-A2.
9. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367-1376.
10. Hanson KE, Slechta ES, Muir H, et al. Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. Abscessus strains: a replacement for 14-day susceptibility testing? J Clin Microbiol 2014; 52:1705-1707.
11. Shallom SJ, Gardina PJ, Myers TG, et al. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacerium massiliense isolates with inducible clarithromycin resistance. J Clin Microbiol 2013; 51:2943-2949.
12. Harada T, Akiyama Y, Kurashima A, et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 2012; 50:3556-3561.
13. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183:405-410.
14. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381:1551-1560.
15. Martiniano SL, Sontag MK, Daley CL, et al. Clinical significance of a first positive nontuberculous myocbacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014; 11:36-44.
16. Catherinot E, Roux AL, Vibet MA, et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros 2013; 12:74-80.
17. Chalermskulrat W, Sood N, Neuringer IP, et al. Nontuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61:507-513.
18. Lobo LJ, Change LC, Esther CR Jr, et al. Lung transplant outcomes in cystic fibrosis patients with preoperative Mycobacterium abscessus respiratory infections. Clin Tranplant 2013; 27:523-529.
19. Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 2012; 25:545-582.
20. Maurer FP, Bruderer VL, Ritter C, et al. Lack of antimicrobial bactericial activity in Mycobacterium abscessus. Antimicrob Agents Chemother 2014; 58:3828-3836.
21. Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014; 11:30-35.
22. Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection. Am J Respir Crit Care Med 2012; 186:917-925.
23. Maurer FP, Castelberg C, Quiblier C, et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of M. Abscessus. J Antimicrob Chemother 2014; 69:1559-1563.
24. Wallace RJ Jr, Dukart G, Brown-Elliott BA, et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother 2014; 69:1945-1953.
25. Shin SJ, Choi GE, Cho SN, et al. Mycobacterial genotypes are associated with clinical manifestation and progression of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis 2013; 57:32-39.